Ilypsa

A therapeutics platform spinout of Symyx that developed novel polymer-based, orally bioavailable therapies for renal failure and metabolic disorders

Biotech & Life Sciences

Sector

Therapeutics platform

Model

01Company Overview

A therapeutics platform spinout of Symyx that developed novel polymer-based, orally bioavailable therapies for renal failure and metabolic disorders. Acquired by Amgen.

02Backed By1 investor

5V5AM Ventures→

03Similar Companies

Is this your company? Claim your profile

T

Tricida

Biotech & Life Sciences

→

AP

Allena Pharmaceuticals

Biotech & Life Sciences

→

KP

KAI Pharmaceuticals

Biotech & Life Sciences

→

AP

ALLYRNA Pharmaceuticals

Biotech & Life Sciences

→

SB

Syntis Bio

Biotech & Life Sciences

→

04Startup DNA

8

signals

Sectors
Business Model
Technology